ArticleDiabetologia2026
Persistent C-peptide secretion is associated with favourable CGM metrics in adults with type 1 diabetes.
Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Commonly used C-peptide assays show differing associations with CGM metrics.Diabetes, obesity & metabolism · 2026Article
- Risk of Hypoglycemia and Associated Factors Among In-Hospital Chinese Patients With Latent Autoimmune Diabetes in Adults (LADA): A Multicenter Retrospective Cohort Study.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisResidual endogenous insulin secretion, reflected by measurable C-peptide, has been linked to improved glycaemic management in type 1 diabetes. We aimed to assess the relationship between random plasma C-peptide levels and continuous glucose monitoring (CGM) metrics in a large, real-world cohort of adults with type 1 diabetes.
methodsWe conducted a cross-sectional analysis of adults with type 1 diabetes attending a single UK centre. Inclusion criteria were diabetes duration >1 year, random plasma glucose >4 mmol/l at C-peptide sampling and ≥70% data completeness on the Freestyle Libre 2 CGM device within the corresponding month. Associations between C-peptide categories (<50 pmol/l to >400 pmol/l) and CGM/HbA
resultsIn total, 945 adults with type 1 diabetes were included with a median age of 45 years (33-57) and median diabetes duration of 18 years (7-29). Of these, 54% were male and median HbA CONCLUSIONS/
interpretationRandom C-peptide measurement in routine care identifies adults with type 1 diabetes who are more likely to achieve CGM and HbA
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.